Vertex reports fourth quarter and full year financial 2022 results

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today reported consolidated financial results for the fourth quarter and full year ended december 31, 2022 and provided full year 2023 financial guidance. “outstanding execution across the company resulted in another year of strong revenue growth as well as acceleration of both the research and clinical-stage pipeline,” said reshma kewalramani, m.d., chief executive officer and president of vertex.
VRTX Ratings Summary
VRTX Quant Ranking